Abstract
Introduction: There is increasing evidence for the involvement of an immune process in the pathophysiology of major depression (MD). Previous studies could demonstrate elevated levels of proinflammatory cytokines as well as elevated PGE2 levels. Celecoxib is a COX–2 inhibitor, leading to a reduced production of PGE2. We conducted a randomized and placebo-controlled trial of celecoxib as add-on therapy in patients with MD treated with reboxetine.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
